Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lars Linderoth is active.

Publication


Featured researches published by Lars Linderoth.


PLOS ONE | 2014

Acylation of Glucagon-Like Peptide-2: Interaction with Lipid Membranes and In Vitro Intestinal Permeability

Sofie Trier; Lars Linderoth; Simon Bjerregaard; Thomas Lars Andresen; Ulrik Lytt Rahbek

Background Acylation of peptide drugs with fatty acid chains has proven beneficial for prolonging systemic circulation as well as increasing enzymatic stability without disrupting biological potency. Acylation has furthermore been shown to increase interactions with the lipid membranes of mammalian cells. The extent to which such interactions hinder or benefit delivery of acylated peptide drugs across cellular barriers such as the intestinal epithelia is currently unknown. The present study investigates the effect of acylating peptide drugs from a drug delivery perspective. Purpose We hypothesize that the membrane interaction is an important parameter for intestinal translocation, which may be used to optimize the acylation chain length for intestinal permeation. This work aims to characterize acylated analogues of the intestinotrophic Glucagon-like peptide-2 by systematically increasing acyl chain length, in order to elucidate its influence on membrane interaction and intestinal cell translocation in vitro. Results Peptide self-association and binding to both model lipid and cell membranes was found to increase gradually with acyl chain length, whereas translocation across Caco-2 cells depended non-linearly on chain length. Short and medium acyl chains increased translocation compared to the native peptide, but long chain acylation displayed no improvement in translocation. Co-administration of a paracellular absorption enhancer was found to increase translocation irrespective of acyl chain length, whereas a transcellular enhancer displayed increased synergy with the long chain acylation. Conclusions These results show that membrane interactions play a prominent role during intestinal translocation of an acylated peptide. Acylation benefits permeation for shorter and medium chains due to increased membrane interactions, however, for longer chains insertion in the membrane becomes dominant and hinders translocation, i.e. the peptides get ‘stuck’ in the cell membrane. Applying a transcellular absorption enhancer increases the dynamics of membrane insertion and detachment by fluidizing the membrane, thus facilitating its effects primarily on membrane associated peptides.


European Journal of Pharmaceutics and Biopharmaceutics | 2015

Acylation of salmon calcitonin modulates in vitro intestinal peptide flux through membrane permeability enhancement.

Sofie Trier; Lars Linderoth; Simon Bjerregaard; Holger M. Strauss; Ulrik Lytt Rahbek; Thomas Lars Andresen

Acylation of peptide drugs with fatty acid chains has proven beneficial for prolonging systemic circulation, as well as increasing enzymatic stability and interactions with lipid cell membranes. Thus, acylation offers several potential benefits for oral delivery of therapeutic peptides, and we hypothesize that tailoring the acylation may be used to optimize intestinal translocation. This work aims to characterize acylated analogues of the therapeutic peptide salmon calcitonin (sCT), which lowers blood calcium, by systematically increasing acyl chain length at two positions, in order to elucidate its influence on intestinal cell translocation and membrane interaction. We find that acylation drastically increases in vitro intestinal peptide flux and confers a transient permeability enhancing effect on the cell layer. The analogues permeabilize model lipid membranes, indicating that the effect is due to a solubilization of the cell membrane, similar to transcellular oral permeation enhancers. The effect is dependent on pH, with larger effect at lower pH, and is impacted by acylation chain length and position. Compared to the unacylated peptide backbone, N-terminal acylation with a short chain provides 6- or 9-fold increase in peptide translocation at pH 7.4 and 5.5, respectively. Prolonging the chain length appears to hamper translocation, possibly due to self-association or aggregation, although the long chain acylated analogues remain superior to the unacylated peptide. For K(18)-acylation a short chain provides a moderate improvement, whereas medium and long chain analogues are highly efficient, with a 12-fold increase in permeability compared to the unacylated peptide backbone, on par with currently employed oral permeation enhancers. For K(18)-acylation the medium chain acylation appears to be optimal, as elongating the chain causes greater binding to the cell membrane but similar permeability, and we speculate that increasing the chain length further may decrease the permeability. In conclusion, acylated sCT acts as its own in vitro intestinal permeation enhancer, with reversible effects on Caco-2 cells, indicating that acylation of sCT may represent a promising tool to increase intestinal permeability without adding oral permeation enhancers.


Amino Acids | 2012

Solid-phase route to Fmoc-protected cationic amino acid building blocks

Jacob Dahlqvist Clausen; Lars Linderoth; Hanne Mørck Nielsen; Henrik Franzyk

Diamino acids are commonly found in bioactive compounds, yet only few are commercially available as building blocks for solid-phase peptide synthesis. In the present work a convenient, inexpensive route to multiple-charged amino acid building blocks with varying degree of hydrophobicity was developed. A versatile solid-phase protocol leading to selectively protected amino alcohol intermediates was followed by oxidation to yield the desired di- or polycationic amino acid building blocks in gram-scale amounts. The synthetic sequence comprises loading of (S)-1-(p-nosyl)aziridine-2-methanol onto a freshly prepared trityl bromide resin, followed by ring opening with an appropriate primary amine, on-resin Nβ-Boc protection of the resulting secondary amine, exchange of the Nα-protecting group, cleavage from the resin, and finally oxidation in solution to yield the target γ-aza substituted building blocks having an Fmoc/Boc protection scheme. This strategy facilitates incorporation of multiple positive charges into the building blocks provided that the corresponding partially protected di- or polyamines are available. An array of compounds covering a wide variety of γ-aza substituted analogs of simple neutral amino acids as well as analogs displaying high bulkiness or polycationic side chains was prepared. Two building blocks were incorporated into peptide sequences using microwave-assisted solid-phase peptide synthesis confirming their general utility.


Archive | 2013

DOUBLE-ACYLATED GLP-1 DERIVATIVES

Patrick William Garibay; Jane Spetzler; János Tibor Kodra; Lars Linderoth; Jesper Lau; Per Sauerberg


Archive | 2010

Glp-1 analogues and derivatives

Christoph Kalthoff; Jesper Lau; Jane Spetzler; Patrick William Garibay; Jacob Kofoed; Lars Linderoth


Archive | 2011

Double-acylated glp-1 derivatives with a linker

Jacob Kofoed; Jesper Lau; Lars Linderoth; Patrick William Garibay; Thomas Kruse


Archive | 2015

Double-Acylated GLP-1 Compounds

Lars Linderoth; Jacob Kofoed; Jesper Lau; Paw Bloch; Patrick William Garibay; János Tibor Kodra


Biochemistry | 2018

α-Helix or β-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4

Alberto Oddo; Sofia Mortensen; Henning Thøgersen; Leonardo De Maria; Stephanie Hennen; James N. McGuire; Jacob Kofoed; Lars Linderoth; Steffen Reedtz-Runge


Archive | 2017

Egf(a) analogues with fatty acid substituents

Jianhe Chen; Jesper Lau; János Tibor Kodra; Birgit Wieczorek; Lars Linderoth; Henning Thøgersen; Salka E. Rasmussen; Patrick William Garibay


Archive | 2015

Composés glp -1 à double acylation

Lars Linderoth; Jacob Kofoed; Jesper Lau; Paw Bloch; Patrick William Garibay; János Tibor Kodra

Collaboration


Dive into the Lars Linderoth's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge